AIMS: To assess the value of @entity3883 measured by equilibrium radionuclide angiography (ERNA) in predicting long-term outcome in cardiac resynchronization therapy (CRT) @entity1 . METHODS AND RESULTS: We reviewed 146 ERNA studies performed in @entity712 @entity1 between 2001 and 2011 at our institution. Long-term follow-up focused on death from any cause or heart transplantation. Phase images were computed using the first harmonic Fourier transform. @entity67 was calculated as the delay between the earliest and most delayed 20% of the left ventricular (LV) (IntraV-20/80) and @entity67 as the difference between LV- and right ventricular (RV)-mode phase angles (InterV). Eighty-three @entity1 (57%) were implanted with a CRT device after ERNA. Median follow-up was 35 [21-50] months. Twenty-four events were observed during the first 41 months. Median baseline ERNA dyssynchrony values were 28 [3 to 46] degrees for intraV-20/80 and 9 [-6 to 24] degrees for interV. Comparing survival between CRT and non-CRT @entity1 according to dyssynchrony status, log-rank tests showed no difference in survival in @entity1 with no ERNA dyssynchrony (P = 0.34) while a significant difference was observed in ERNA @entity1 with high level of @entity3883 (P = 0.004). CONCLUSION: ERNA @entity3883 could be of value in CRT @entity1 selection.

Value of XXXX as assessed by radionuclide ventriculography to predict the cardiac resynchronization therapy response.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity3883 :: ('MESH:D041781', 'Disease') :: ['mechanical dyssynchrony'] @entity67 :: ('MESH:D018754', 'Disease') :: ['inter-ventricular dyssynchrony', 'Intra-ventricular dyssynchrony'] @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure']
@entity3883 :: (MESH:D041781,Disease) :: ['mechanical dyssynchrony']
